U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H13N5O4
Molecular Weight 267.2413
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ZIDOVUDINE

SMILES

CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O

InChI

InChIKey=HBOMLICNUCNMMY-XLPZGREQSA-N
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H13N5O4
Molecular Weight 267.2413
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019910s033lbl.pdf

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zidovudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Zidovudine, a structural analog of thymidine, is a prodrug that must be phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). It inhibits the activity of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. It competes with the natural substrate dGTP and incorporates itself into viral DNA. It is also a weak inhibitor of cellular DNA polymerase α and γ. Zidovudine is used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections. Zidovudine is marketed as Retrovir.

Originator

Curator's Comment: Zidovudine had initially been synthesized by Dr. Jerome Horwitz and associates in 1964 at the Michigan Cancer Foundation as a potential anticancer agent

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RETROVIR

Approved Use

RETROVIR is a nucleoside analogue reverse transcriptase inhibitor indicated for: -- Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) -- Prevention of maternal-fetal HIV-1 transmission. (1.2)

Launch Date

5.43023989E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.1 μg/mL
2.5 mg/kg 6 times / day steady-state, intravenous
dose: 2.5 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.2 μg/mL
50 mg 6 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.55 μg/mL
100 mg 6 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1 μg/mL
250 mg 6 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.8 μg/mL
150 mg 6 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.16 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.74 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.72 μg/mL
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1400 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.32 mg × h/L
50 mg 6 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.65 mg × h/L
100 mg 6 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.28 mg × h/L
250 mg 6 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.31 mg × h/L
150 mg 6 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.26 mg × h/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.39 mg × h/L
60 mg single, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.74 mg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.22 mg × h/L
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.33 mg × h/L
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.4 h
50 mg 6 times / day steady-state, oral
dose: 50 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.1 h
100 mg 6 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.1 h
250 mg 6 times / day steady-state, oral
dose: 250 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.4 h
150 mg 6 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.3 h
60 mg single, intravenous
dose: 60 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.7 h
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.5 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZIDOVUDINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
62%
2.5 mg/kg 6 times / day steady-state, intravenous
dose: 2.5 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
ZIDOVUDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Sources:
unhealthy, 28 years
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: 28 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Anemia...
AEs leading to
discontinuation/dose reduction:
Anemia (grade 1, 1 patient)
Sources:
1000 mg 1 times / day steady, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: steady
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1, homosexual
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Other AEs: Depression...
Other AEs:
Depression (1 patient)
Sources:
22.5 g single, oral
Overdose
Dose: 22.5 g
Route: oral
Route: single
Dose: 22.5 g
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1, homosexual
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Dizziness, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Dizziness (1 patient)
Diarrhoea (1 patient)
Sources:
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Co-administed with::
temazepam
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Drowsiness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1 patient)
Sources:
36 g single, oral
Overdose
Dose: 36 g
Route: oral
Route: single
Dose: 36 g
Sources:
unhealthy, 35 years
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: 35 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Seizure...
AEs leading to
discontinuation/dose reduction:
Seizure (1 patient)
Sources:
134 mg single, oral
Overdose
Dose: 134 mg
Route: oral
Route: single
Dose: 134 mg
Sources:
healthy, 4 day
n = 1
Health Status: healthy
Condition: HIV postnatal prophylaxis
Age Group: 4 day
Sex: F
Population Size: 1
Sources:
Disc. AE: Metabolic acidosis exacerbated...
AEs leading to
discontinuation/dose reduction:
Metabolic acidosis exacerbated (1 patient)
Sources:
8000 mg/m2 multiple, intravenous
MTD
Dose: 8000 mg/m2
Route: intravenous
Route: multiple
Dose: 8000 mg/m2
Co-administed with::
5-fluorouracil(500 mg/m2)
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: metastatic colorectal cancer
Age Group: adult
Sex: unknown
Population Size: 29
Sources:
Disc. AE: Cardiac arrhythmia...
Other AEs: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cardiac arrhythmia (grade 5, 1 patient)
Other AEs:
Diarrhea (grade 3-4, 17%)
Sources:
40 g single, oral
Overdose
Dose: 40 g
Route: oral
Route: single
Dose: 40 g
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 1
Sources:
Disc. AE: Nystagmus...
AEs leading to
discontinuation/dose reduction:
Nystagmus (1 patient)
Sources:
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Other AEs: Asthenia, Headache...
Other AEs:
Asthenia (9%)
Headache (63%)
Malaise (53%)
Anorexia (20%)
Constipation (6%)
Nausea (51%)
Vomiting (17%)
Anemia (1%)
Granulocytopenia (2%)
Sources:
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Other AEs: Fever, Hepatomegaly...
Other AEs:
Fever (25%)
Hepatomegaly (11%)
Nausea and vomiting (8%)
Diarrhea (8%)
Stomatitis (6%)
Splenomegaly (5%)
Cough (15%)
Breath sounds abnormal (7%)
Ear disorders NEC (7%)
Congestion nasal (8%)
Skin rash (12%)
Lymphadenopathy (9%)
Neutropenia (8%)
Thrombocytopenia (1%)
ALT (grade 3, 1%)
Lipase (3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anemia grade 1, 1 patient
Disc. AE
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Sources:
unhealthy, 28 years
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: 28 years
Sex: M
Population Size: 1
Sources:
Depression 1 patient
1000 mg 1 times / day steady, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: steady
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1, homosexual
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Diarrhoea 1 patient
Disc. AE
22.5 g single, oral
Overdose
Dose: 22.5 g
Route: oral
Route: single
Dose: 22.5 g
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1, homosexual
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Dizziness 1 patient
Disc. AE
22.5 g single, oral
Overdose
Dose: 22.5 g
Route: oral
Route: single
Dose: 22.5 g
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1, homosexual
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Drowsiness 1 patient
Disc. AE
20000 mg single, oral
Overdose
Dose: 20000 mg
Route: oral
Route: single
Dose: 20000 mg
Co-administed with::
temazepam
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Seizure 1 patient
Disc. AE
36 g single, oral
Overdose
Dose: 36 g
Route: oral
Route: single
Dose: 36 g
Sources:
unhealthy, 35 years
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: 35 years
Sex: M
Population Size: 1
Sources:
Metabolic acidosis exacerbated 1 patient
Disc. AE
134 mg single, oral
Overdose
Dose: 134 mg
Route: oral
Route: single
Dose: 134 mg
Sources:
healthy, 4 day
n = 1
Health Status: healthy
Condition: HIV postnatal prophylaxis
Age Group: 4 day
Sex: F
Population Size: 1
Sources:
Diarrhea grade 3-4, 17%
8000 mg/m2 multiple, intravenous
MTD
Dose: 8000 mg/m2
Route: intravenous
Route: multiple
Dose: 8000 mg/m2
Co-administed with::
5-fluorouracil(500 mg/m2)
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: metastatic colorectal cancer
Age Group: adult
Sex: unknown
Population Size: 29
Sources:
Cardiac arrhythmia grade 5, 1 patient
Disc. AE
8000 mg/m2 multiple, intravenous
MTD
Dose: 8000 mg/m2
Route: intravenous
Route: multiple
Dose: 8000 mg/m2
Co-administed with::
5-fluorouracil(500 mg/m2)
Sources:
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: metastatic colorectal cancer
Age Group: adult
Sex: unknown
Population Size: 29
Sources:
Nystagmus 1 patient
Disc. AE
40 g single, oral
Overdose
Dose: 40 g
Route: oral
Route: single
Dose: 40 g
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 1
Sources:
Anemia 1%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Vomiting 17%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Granulocytopenia 2%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Anorexia 20%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Nausea 51%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Malaise 53%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Constipation 6%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Headache 63%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Asthenia 9%
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, adult
n = 453
Health Status: unhealthy
Condition: HIV-1
Age Group: adult
Sex: unknown
Population Size: 453
Sources:
Thrombocytopenia 1%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Hepatomegaly 11%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Skin rash 12%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Cough 15%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Fever 25%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Lipase 3%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Splenomegaly 5%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Stomatitis 6%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Breath sounds abnormal 7%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Ear disorders NEC 7%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Congestion nasal 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Diarrhea 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Nausea and vomiting 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Neutropenia 8%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
Lymphadenopathy 9%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
ALT grade 3, 1%
160 mg/m2 3 times / day steady, oral
Recommended
Dose: 160 mg/m2, 3 times / day
Route: oral
Route: steady
Dose: 160 mg/m2, 3 times / day
Co-administed with::
EPIVIR(4 mg/kg twice daily)
Sources:
unhealthy, children
n = 236
Health Status: unhealthy
Condition: HIV-1
Age Group: children
Sex: unknown
Population Size: 236
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 <400 uM]
no [IC50 <500 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
no
no
no
no
weak [IC50 31.34 uM]
yes [Ki 1200 uM]
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major [Km 770 uM]
yes (pharmacogenomic study)
Comment: Km (Pooled HLMs) = 1.4 mM; The carriers of UGT2B7*1c had 57% lower mean AUC (P = 0.029, unpaired t-test), 196% higher mean CL/F (P = 0.004, unpaired t-test) (Figure 3B), and 67% shorter mean elimination half-life (P = 0.030, unpaired t-test) compared with non-carriers.
minor
minor
no
no
no
no
no
no
no
no
no
yes [Km 145.1 uM]
yes [Km 151.8 uM]
yes [Km 2400 uM]
yes [Km 26.8 uM]
yes [Km 45.9 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
In vitro anti-hepatitis B virus activities of 5"-O-myristoyl analogue derivatives of 3"-fluoro-2",3"-dideoxythymidine (FLT) and 3"-azido-2",3"-dideoxythymidine (AZT).
1998 Sep-Dec
Synthesis of 4'-substituted nucleosides and their biological evaluation.
1999
Synthesis and anti-HIV activity of unusual nucleoside oxanosine derivatives.
1999
Synthesis and anti-HIV activity of some S-acyl-2-thioethyl (SATE) phosphoramidate derivatives of 3'-azido-2',3'-dideoxythymidine.
1999 Apr-May
Antiviral nucleoside drug delivery via amino acid phosphoramidates.
1999 Apr-May
Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT.
1999 Apr-May
Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.
1999 Apr-May
"Mixed inhibitors" of HIV-reverse transcriptase: synthesis and antiviral activity.
1999 Apr-May
Long-term effects of prenatal 3'-azido-3'-deoxythymidine (AZT) exposure on intermale aggressive behaviour of mice.
1999 Aug
Synthesis and antiviral activity of phosphoralaninate derivatives of methylenecyclopropane analogues of nucleosides.
1999 Aug
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
1999 Aug
Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
1999 Aug
Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.
1999 Dec
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
1999 Dec 20
Inhibition of beta-globin gene expression by 3'-azido-3'-deoxythymidine in human erythroid progenitor cells.
1999 Dec 31
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
1999 Jul
Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage.
1999 Jul 1
Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents.
1999 Jul 15
Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis.
1999 Jul 19
A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.
1999 Jun
Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.
1999 Jun
WHI-05, a novel bromo-methoxy substituted phenyl phosphate derivative of zidovudine, is a dual-action spermicide with potent anti-HIV activity.
1999 May
Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine.
1999 May
Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities.
1999 May
Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217.
1999 Nov
Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice.
1999 Nov 15
In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.
1999 Oct
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
1999 Oct
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.
1999 Oct 1
Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT.
1999 Oct 19
Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
1999 Oct 21
Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
1999 Sep
Anti-AIDS agents. Part 36: 17-carboxylated steroids as potential anti-HIV agents.
1999 Sep
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
1999 Sep 20
The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans.
1999 Sep 24
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.
1999 Sep 25
Prophylactic contraceptives for HIV/AIDS.
1999 Sep-Oct
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
2000 Apr 10
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
2000 Aug
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine.
2000 Feb
Cytochrome c oxidase deficiency in the muscle of patients with zidovudine myopathy is segmental and affects both mitochondrial DNA- and nuclear DNA-encoded subunits.
2000 Jul
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
2000 Jul 4
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
2000 Jun 10
Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents.
2000 Mar
Syntheses of oxanosine and carbocyclic oxanosine derivatives as anti-HIV agents.
2000 Mar
Coumarins and bicoumarin from Ferula sumbul: anti-HIV activity and inhibition of cytokine release.
2000 Mar
Spiropentane mimics of nucleosides: analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, isomeric assignment, and biological activity.
2000 Mar 10
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
2000 May
3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7).
2000 May
Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
2000 May 1
Patents

Sample Use Guides

Treatment of HIV-1 infection: Adults: 600 mg/day in divided doses with other antiretroviral agents. Pediatric patients (6 weeks to <18 years of age): Dosage should be calculated based on body weight not to exceed adult dose.
Route of Administration: Oral
The antiviral activity of CD8(+) cells from 2 LTSs was inhibited by 5 uM of zidovudine.
Substance Class Chemical
Created
by admin
on Sun Dec 18 18:21:20 UTC 2022
Edited
by admin
on Sun Dec 18 18:21:20 UTC 2022
Record UNII
4B9XT59T7S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZIDOVUDINE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
ZIDOVUDINE [EP MONOGRAPH]
Common Name English
BW-A509U
Code English
AZIDOTHYMIDINE
Systematic Name English
3'-DEOXY-3'-AZIDOTHYMIDINE
Systematic Name English
THYMIDINE, 3'-AZIDO-3'-DEOXY-
Systematic Name English
ZDV
Common Name English
ZIDOVUDINE [MI]
Common Name English
COMBIVIR COMPONENT ZIDOVUDINE
Common Name English
ZIDOVUDINE [USP-RS]
Common Name English
ZIDOVUDINE [EP IMPURITY]
Common Name English
AZT
Common Name English
ZIDOVUDINE COMPONENT OF TRIZIVIR
Brand Name English
TRIZIVIR COMPONENT ZIDOVUDINE
Brand Name English
ZIDOVUDINE [IARC]
Common Name English
ZIDOVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA
Brand Name English
ZIDOVUDINE COMPONENT OF COMBIVIR
Common Name English
ZIDOVUDINE [USAN]
Common Name English
ZIDOVUDINE [JAN]
Common Name English
COMPOUND S
Code English
ZIDOVUDINE [EMA EPAR]
Common Name English
ZIDOVUDINE [ORANGE BOOK]
Common Name English
ZIDOVUDINE [VANDF]
Common Name English
RETROVIR
Brand Name English
3'-AZIDO-3'-DEOXYTHYMIDINE
Systematic Name English
ZIDOVUDINE [MART.]
Common Name English
ZIDOVUDINE [USP MONOGRAPH]
Common Name English
3'-AZT
Common Name English
ZIDOVUDINE [WHO-IP]
Common Name English
3'-AZIDOTHYMIDINE
Systematic Name English
ZIDOVUDINE [HSDB]
Common Name English
zidovudine [INN]
Common Name English
BW-A-509U
Code English
NSC-602670
Code English
Zidovudine [WHO-DD]
Common Name English
ZIDOVUDINUM [WHO-IP LATIN]
Common Name English
LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT ZIDOVUDINE
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
FDA ORPHAN DRUG 8185
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-VATC QJ05AR04
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-ATC J05AR05
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-ATC J05AF01
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NDF-RT N0000175462
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-VATC QJ05AR01
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-ATC J05AR04
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NCI_THESAURUS C1557
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NDF-RT N0000175459
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NCI_THESAURUS C97452
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NDF-RT N0000009947
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NDF-RT N0000175459
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
EMA ASSESSMENT REPORTS LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-ATC J05AR01
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-VATC QJ05AR05
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
WHO-VATC QJ05AF01
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
LIVERTOX NBK548210
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
NDF-RT N0000175459
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
ZIDOVUDINE
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY Description: A white or brownish powder. Solubility: Soluble in ethanol (~750 g/l) TS, sparingly soluble in water. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Zidovudine should be kept in a tightly closed container, protected from light. Additional information: Zidovudine may exhibit polymorphism. Definition: Zidovudine contains not less than 97.0% and not more than 103.0% of C10H13N5O4, calculated with reference to the dried substance.
USAN
Y-51
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
NCI_THESAURUS
C947
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
DRUG CENTRAL
2861
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
CAS
30516-87-1
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
MESH
D015215
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
LACTMED
Zidovudine
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
RS_ITEM_NUM
1724500
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
IUPHAR
4825
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
FDA UNII
4B9XT59T7S
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
RXCUI
11413
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY RxNorm
DRUG BANK
DB00495
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
EPA CompTox
DTXSID8020127
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
EVMPD
SUB00153MIG
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
MERCK INDEX
M11592
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY Merck Index
DAILYMED
4B9XT59T7S
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
WIKIPEDIA
ZIDOVUDINE
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
ChEMBL
CHEMBL129
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
NSC
602670
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
PUBCHEM
35370
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
HSDB
6515
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
INN
6118
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
CHEBI
10110
Created by admin on Sun Dec 18 18:21:24 UTC 2022 , Edited by admin on Sun Dec 18 18:21:24 UTC 2022
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
TRANSPORTER -> NON-SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> NON-SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
AMOUNT FORMED FOLLOWING ADMINISTRATION
MINOR
METABOLITE TOXIC -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
AMOUNT OF EXCRETED
MAJOR
Related Record Type Details
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity C (thymine) about 0.3. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1): - the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.6, is not greater than four times the area of the principal peak in the chromatogram obtained with solution (2) (2.0%).
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity B about 1.2. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1):- the area of any peak corresponding to impurity B, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (1.0%).
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
IMPURITY -> PARENT
IMPURITY -> PARENT
The impurity peaks are eluted at the following relative retention times with reference to zidovudine (retention time about 12 to 13 minutes): impurity A (stavudine) about 0.4;. The test is not valid unless the resolution factor between the peaks due to zidovudine and impurity B is at least 2. In the chromatogram obtained with solution (1):- the area of any peak corresponding to impurity A, when multiplied by a correction factor of 0.9, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%).
IMPURITY -> PARENT
IMPURITY -> PARENT
Not Specified
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC Population
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Populations
PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Polpulation
PHARMACOKINETIC